Health
The U.S. government will no longer penalize American companies for making six popular peptides
By Marcus Chen
Chinese drug sector’s stature grows at major cancer conference
Marcus Chen
Marcus Chen
Managing Editor · St. Paul, MN
Marcus manages the day-to-day editorial workflow across all brands, coordinating coverage assignments and ensuring editorial standards are met. He previously served as city editor at the Pioneer Press and holds a degree in Political Science from Carleton College.
More from Marcus →Managing Editor · Wednesday, October 28, 2026 at 10:00 AM · 1 min read
An array of Chinese drug makers showcased positive trial results for new cancer treatments at a major European medical conference, underscoring the expanding international influence of China’s biotech sector. Domestic innovative drugs, particularly antibody-drug conjugates (ADCs), delivered impressive data across multiple tumour types at the European Society for Medical Oncology (Esmo) Congress, with some early-stage data further showing the country’s “innovation capabilities”, said analysts...
Up nextThe U.S. government will no longer penalize American companies for making six popular peptidesHealth · 5 min read
